| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Lymphoma | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Central Nervous System Neoplasms | |||||
| Nervous System Neoplasms | |||||
| 3 | More general conditions related to this trial | ||||
| Immune System Diseases | |||||
| Immunoproliferative Disorders | |||||
| Lymphatic Diseases | |||||
| Lymphoproliferative Disorders | |||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| Neoplasms by Site | |||||
| Nervous System Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| exatecan mesylate | |||||
| filgrastim | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| DX 8951 | |||||
| 6 | More general drug interventions related to this trial | ||||
| Antineoplastic Agents | |||||
| Antineoplastic Agents, Phytogenic | |||||
| Enzyme Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| Daiichi Sankyo Inc. | |||||
|
